CYCC Financial Facts
Operating loss: -3.48MIncome tax benefit: 454K
See Full Income Statement
Accrued liabilities and other current liabilities: 3.56M
Total assets: 22.65M
See Full Balance Sheet
Cyclacel Pharmaceuticals (CYCC) Earnings
|
Expand Research on CYCC
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | 0.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -8.9% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/13/25 | Q225 | -$0.98 | $0.00 | -$0.98 | N/A | N/A | N/A |  | | Details | |
| 8/13/25 | Q225 | -$0.98 | $0.00 | -$0.98 | N/A | N/A | N/A | | | Details | |
| 4/3/25 | Q424 | -$0.33 | $0.00 | -$0.33 | N/A | N/A | N/A | | | Details | |
| 11/12/24 | Q324 | -$0.18 | $0.00 | -$0.18 | $10K | N/A | N/A | | | Details | |
| 11/30/-1 | Q124 | -$2.27 | $0.00 | -$2.27 | N/A | N/A | N/A | | | Details | |
| 3/27/24 | Q423 | N/A | -$0.41 | N/A | N/A | N/A | N/A | N/A | N/A | ||
11/13/23  |
Q323 | N/A | -$0.36 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 8/9/23 | Q223 | -$0.44 | -$0.50 | +$0.06 | $370K | N/A | N/A | | | Details |
